HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hasem Habelhah Selected Research

TNF Receptor-Associated Factor 2 (TRAF2)

4/2016TRAF2 exerts opposing effects on basal and TNFα-induced activation of the classic IKK complex in hematopoietic cells in mice.
10/2015RIP1 Cleavage in the Kinase Domain Regulates TRAIL-Induced NF-κB Activation and Lymphoma Survival.
2/2015TRAIL activates JNK and NF-κB through RIP1-dependent and -independent pathways.
12/2012IκB kinase ε phosphorylates TRAF2 to promote mammary epithelial cell transformation.
1/2011TRAF2 phosphorylation promotes NF-κB-dependent gene expression and inhibits oxidative stress-induced cell death.
4/2009Phosphorylation of TRAF2 within its RING domain inhibits stress-induced cell death by promoting IKK and suppressing JNK activation.
1/2009TRAF2 phosphorylation modulates tumor necrosis factor alpha-induced gene expression and cell resistance to apoptosis.
1/2004Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hasem Habelhah Research Topics

Disease

8Neoplasms (Cancer)
01/2020 - 01/2009
5Lymphoma (Lymphomas)
01/2020 - 01/2004
3Inflammation (Inflammations)
05/2014 - 07/2010
1Myeloid Leukemia (Leukemia, Myelocytic)
01/2020
1Multiple Myeloma
01/2018
1Diarrhea
04/2016
1Adenocarcinoma
05/2014
1Adenoma (Adenomas)
05/2014
1Foreign Bodies (Foreign Body)
05/2014
1Colonic Neoplasms (Colon Cancer)
05/2014
1Carcinogenesis
05/2014
1Breast Neoplasms (Breast Cancer)
12/2012
1B-Cell Lymphoma (Lymphoma, B Cell)
01/2011
1Hodgkin Disease (Hodgkin's Disease)
04/2009
1Melanoma (Melanoma, Malignant)
08/2005
1Hypoxia (Hypoxemia)
06/2004

Drug/Important Bio-Agent (IBA)

8TNF Receptor-Associated Factor 2 (TRAF2)IBA
04/2016 - 01/2004
3Transcription Factors (Transcription Factor)IBA
01/2020 - 07/2010
3NF-kappa B (NF-kB)IBA
04/2009 - 01/2004
2Proteasome Endopeptidase Complex (Proteasome)IBA
01/2018 - 06/2004
2Phosphotransferases (Kinase)IBA
10/2015 - 12/2012
2Death Domain ReceptorsIBA
02/2015 - 07/2010
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
04/2009 - 01/2009
1Pharmaceutical PreparationsIBA
01/2020
1DNA (Deoxyribonucleic Acid)IBA
01/2020
1A-Form DNA (A-DNA)IBA
01/2020
1Green Fluorescent ProteinsIBA
01/2020
1Antineoplastic Agents (Antineoplastics)IBA
10/2015
1LigandsIBA
02/2015
1CaspasesIBA
05/2014
1fascinIBA
05/2014
1Complementary DNA (cDNA)IBA
05/2014
1Small Interfering RNA (siRNA)IBA
08/2005
1UbiquitinIBA
06/2004
1Ligases (Synthetase)IBA
06/2004
1Hemoglobins (Hemoglobin)IBA
06/2004
1Prolyl Hydroxylases (Prolyl Hydroxylase)IBA
06/2004

Therapy/Procedure

1Ligation
10/2015